(Kurz: Überprüfung der Therapiestandards für die Polyartikuläre JIA)
1)To assess the clinical benefit (remission) in subjects with poly JIA treated following international recommendations. JADAS remission as defined by a JADAS10 ≤ 1 compared to historical patients documented in the German BIKER registry
2)To assess the clinical benefit according to the JADAS definition of minimal disease activity (JADAS10 ≤3.8), the Ped ACR JIA 30%/50%/70%/90% and 100% improvement and inactive disease as defined according to the proposed criteria for inactive disease and remission of Wallace et al. (13)
To assess the long-term safety of routine medication in subjects with poly JIA.